NCT02433522View on ClinicalTrials.gov

Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab

PHASE3CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 16, 2018

Study Completion Date

August 16, 2018

Conditions
ANCA-associated Vasculitides
Interventions
DRUG

rituximab

500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.

DRUG

Placebo

Trial Locations (1)

75014

Hopital cochin, Paris

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02433522 - Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab | Biotech Hunter | Biotech Hunter